Addressing infectious diseases
Our company is committed to developing and implementing scientific advancement in infection and vaccines. We work to protect patients against the burden of influenza and bacterial infections, particularly those resistant to current antibiotics.
In Asia alone, antimicrobial resistance results in 225,000 deaths from hospital-acquired infections, while there are 3-5 million severe cases of influenza each year worldwide. Demand for health interventions to address these burdens of disease remains high and, through working with the wider infection community, Tangent Pharma aims to translate science into solutions to address global challenges faced in these disease areas.
Our focus on infectious diseases: Infectious diseases are the second-leading cause of death worldwide, after heart disease, and are responsible for more deaths annually than cancer.
Antimicrobial resistance (AMR): AMR is a major public health threat. As bacteria develop resistance to current antibiotics, deadly infections could, again, become uncontrollable.
Seasonal influenza is a serious public health problem that causes severe illness and death in high-risk populations.